http://www.genengnews.com/news/bnitem.aspx?name=1060340XSL_NEWSML_TO_NEWSML_WEB.xml

Breaking News

Aethlon Medical Launches Hepatitis-C Clinical Trial
9/20/2005 10:57:00 AM EST

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that human clinical
trials to treat patients infected with the Hepatitis-C virus (HCV) are now
underway at the Apollo Hospital in New Delhi, India. The primary objective
of the trial is to demonstrate the safety of Aethlon's Hemopurifier(TM)
treatment technology. The secondary objective of the trial will be to obtain
preliminary efficacy data related to serologic and virologic markers,
including viral load measurements before and after treatment with the
Hemopurifier(TM).

Aethlon Chairman and CEO, James A. Joyce, stated, "Five years ago, our
vision that a device could capture circulating viruses and toxins was purely
conceptual. Today, I thank the researchers, advisors, and shareholders who
were instrumental in executing the development phase of our vision." Joyce
continued, "As a result, we now have the opportunity to demonstrate the
safety and effectiveness of our device in a clinical setting. If successful,
we will provide new hope to those afflicted with Hepatitis-C and other
infectious diseases."

According to the World Health Organization, Hepatitis-C (HCV) is a global
disease with approximately 190 million persons infected. The infected
population in India exceeds 12.5 million. In the United States, HCV is the
most common blood-born infection with approximately 3.9 million citizens
infected. HCV is a leading cause for liver disease and the most common
reason for liver transplantation. Unfortunately, only 50% of HCV infected
respond to the current standard of Interferon and Ribavirin treatment.
Interferon and Ribavirin regimens are expensive and are known to have
serious side effects.

Individuals enrolled in the initial trial are HCV-infected patients that
require kidney dialysis as a result of End Stage Renal Disease (ESRD).
Approximately 30-35% of all ESRD patients are infected with HCV, and as a
result of their condition, are unable to endure the toxicity of HCV drug
treatment. Follow-on studies are planned to evaluate the ability of the
Hemopurifier to improve patient response rates to Interferon and Ribavirin
as a conjunctive therapy, and as a stand-alone treatment for patients who
are either unable to endure or do not respond to the current standard of
care. The trial will also serve as a means to obtain human safety data,
which will be submitted in conjunction with planned regulatory initiatives
to treat the Human Immunodeficiency Virus (HIV) and drug and vaccine
resistant Biological Weapons. Initial safety data and preliminary efficacy
observations from the trial are expected to be available within the next
sixty days.

About Aethlon Medical

Aethlon Medical is pioneering the development of immunotherapeutic devices
able to mimic the immune response of clearing viruses and viral toxins from
circulation. The Company's lead product, the Hemopurifier(TM), converges the
established principals of hemodialysis and affinity chromatography with the
discovery of compounds that effectively adhere to the surface of a multiple
envelope viruses. The Hemopurifier(TM) is targeted to treat acute and
chronic infectious diseases, including, drug and vaccine resistant
Biological Weapons, the Human Immunodeficiency Virus (HIV), and the
Hepatitis-C Virus (HCV). The Company has an experienced management team,
which receives support and guidance from globally recognized science and
regulatory advisors representing the infectious disease, biowarfare, and
dialysis industries. More information on Aethlon Medical and the
Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the development
of its planned products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety
of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.